Keros Therapeutics, Inc. (NASDAQ:KROS) Given Average Recommendation of “Buy” by Brokerages

Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) have earned a consensus recommendation of “Buy” from the seven ratings firms that are currently covering the firm, Marketbeat reports. Seven equities research analysts have rated the stock with a buy recommendation. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $86.00.

Several equities research analysts recently issued reports on KROS shares. Piper Sandler reiterated an “overweight” rating and issued a $105.00 price target on shares of Keros Therapeutics in a research note on Wednesday, March 27th. Wedbush reiterated an “outperform” rating and issued a $86.00 price target on shares of Keros Therapeutics in a research note on Thursday, February 29th. Truist Financial reiterated a “buy” rating and issued a $100.00 price target on shares of Keros Therapeutics in a research note on Wednesday, March 13th. William Blair reiterated an “outperform” rating on shares of Keros Therapeutics in a research note on Wednesday, February 21st. Finally, HC Wainwright reiterated a “buy” rating and issued a $100.00 price target on shares of Keros Therapeutics in a research note on Friday, March 1st.

Institutional Trading of Keros Therapeutics

Large investors have recently bought and sold shares of the business. Virtus ETF Advisers LLC boosted its position in shares of Keros Therapeutics by 7.1% during the 4th quarter. Virtus ETF Advisers LLC now owns 2,743 shares of the company’s stock worth $109,000 after purchasing an additional 182 shares in the last quarter. Wellington Management Group LLP boosted its position in shares of Keros Therapeutics by 1.2% during the 1st quarter. Wellington Management Group LLP now owns 18,984 shares of the company’s stock worth $1,032,000 after purchasing an additional 227 shares in the last quarter. California State Teachers Retirement System boosted its position in shares of Keros Therapeutics by 1.9% during the 3rd quarter. California State Teachers Retirement System now owns 19,511 shares of the company’s stock worth $734,000 after purchasing an additional 364 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Keros Therapeutics by 3.2% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,898 shares of the company’s stock worth $513,000 after purchasing an additional 404 shares in the last quarter. Finally, Amalgamated Bank lifted its position in Keros Therapeutics by 15.6% in the 4th quarter. Amalgamated Bank now owns 3,245 shares of the company’s stock valued at $156,000 after acquiring an additional 439 shares in the last quarter. 71.56% of the stock is currently owned by institutional investors and hedge funds.

Keros Therapeutics Trading Up 1.8 %

Keros Therapeutics stock opened at $61.90 on Friday. Keros Therapeutics has a 12 month low of $27.02 and a 12 month high of $73.00. The stock’s 50 day moving average is $63.10 and its 200-day moving average is $45.89. The company has a market capitalization of $2.23 billion, a price-to-earnings ratio of -11.90 and a beta of 1.26.

Keros Therapeutics (NASDAQ:KROS) last posted its earnings results on Friday, March 1st. The company reported ($1.34) EPS for the quarter, beating the consensus estimate of ($1.37) by $0.03. The firm had revenue of $0.14 million during the quarter. During the same quarter last year, the firm earned ($1.09) earnings per share. As a group, equities research analysts predict that Keros Therapeutics will post -5.11 earnings per share for the current fiscal year.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.